オンコセラピー・サイエンス remained loss-making. In the first quarter of the fiscal year ending March 2027, revenue was approximately ¥170 million, operating loss was approximately ¥280 million and net loss was approximately ¥290 million, confirming the continuation of losses.
According to a summary of the earnings report released on 7 August 2026, business revenue in the first quarter of the fiscal year ending March 2027 was ¥170.77 million, operating loss was ¥285.14 million and net loss was ¥288.94 million, with losses continuing. Although the loss narrowed from the same period of the previous year, substantial doubt regarding the going concern assumption was reported, and the earnings forecast was not disclosed.
Performance over the past 12 quarters has been challenging, with net profit margin and operating profit margin remaining negative. Although the rise in the equity ratio indicates an improvement in stability, the earnings environment continues to be viewed as fragile.
Points of focus going forward include the potential contribution to revenue from continued orders for whole-genome analysis and the operation of testing facilities. Risks have also been identified, including the funding burden caused by research and development costs preceding revenue generation and fluctuations in the timing of revenue recognition depending on the contractual structure.
Overall, continued orders for analysis services and progress in the pipeline could affect performance, while factors that put pressure on cash flow remain.